Department of Genetics, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa.
Unit for Cardiac and Cardiovascular Genetics, Department of Medical Genetics, Oslo University Hospital, Nydalen, P.O. Box 4956, 0424, Oslo, Norway.
Genetica. 2021 Feb;149(1):1-19. doi: 10.1007/s10709-021-00113-x. Epub 2021 Jan 30.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a central role in cholesterol homeostasis in humans as a major regulator of LDLR levels. PCSK9 is an intriguing protease in that it does not act by proteolysis but by preventing LDLR recirculation from endosomes to the plasma membrane. This, and the inexistence of any other proteolytic substrate but itself could suggest that PCSK9 is an exquisite example of evolutionary fine-tuning. However, the gene has been lost in several mammalian species, and null alleles are present (albeit at low frequencies) in some human populations without apparently deleterious health effects, raising the possibility that the PCSK9 may have become dispensable in the mammalian lineage. To address this issue, we systematically recovered, assembled, corrected, annotated and analysed publicly available PCSK9 sequences for 420 eutherian species to determine the distribution, frequencies, mechanisms and timing of PCSK9 pseudogenization events, as well as the evolutionary pressures underlying the preservation or loss of the gene. We found a dramatic difference in the patterns of PCSK9 retention and loss between Euarchontoglires-where there is strong pressure for gene preservation-and Laurasiatheria, where multiple independent events have led to PCSK9 loss in most species. These results suggest that there is a fundamental difference in the regulation of cholesterol metabolism between Euarchontoglires and Laurasiatheria, which in turn has important implications for the use of Laurasiatheria species (e.g. pigs) as animal models of human cholesterol-related diseases.
前蛋白转化酶枯草溶菌素 9(PCSK9)在人类胆固醇稳态中发挥核心作用,是 LDLR 水平的主要调节因子。PCSK9 是一种有趣的蛋白酶,它不是通过蛋白水解作用发挥作用,而是通过阻止 LDLR 从内体再循环到质膜。这一点,以及除了它本身之外没有其他蛋白水解底物,可以表明 PCSK9 是进化微调的一个极好例子。然而,该基因在几种哺乳动物物种中已经丢失,并且在一些人类群体中存在无效等位基因(尽管频率较低),但没有明显的健康影响,这增加了 PCSK9 在哺乳动物谱系中可能变得可有可无的可能性。为了解决这个问题,我们系统地回收、组装、纠正、注释和分析了 420 种真兽类物种的公开可用的 PCSK9 序列,以确定 PCSK9 假基因化事件的分布、频率、机制和时间,以及基因保留或丢失背后的进化压力。我们发现,PCSK9 的保留和丢失模式在真兽类动物(Euarchontoglires)和劳亚兽类动物(Laurasiatheria)之间存在显著差异——在前者中,基因保留的压力很强,而在后者中,多个独立的事件导致大多数物种的 PCSK9 丢失。这些结果表明,Euarchontoglires 和 Laurasiatheria 之间的胆固醇代谢调节存在根本差异,这反过来又对使用 Laurasiatheria 物种(例如猪)作为人类胆固醇相关疾病的动物模型产生了重要影响。